About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Biostatistics and Epidemiology
›
top-articles
Department of Biostatistics and Epidemiology
11
(top 5%)
papers
573
(top 2%)
citations
11
(top 2%)
h
-index
11
(top 5%)
g
-index
11
all documents
593
doc citations
258
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Pain outcomes in patients with advanced breast cancer and bone metastases
Cancer
2013
126
2
Hospitalization risks related to vascular access type among incident US hemodialysis patients
Nephrology Dialysis Transplantation
2011
94
3
Conversion of Vascular Access Type Among Incident Hemodialysis Patients: Description and Association With Mortality
American Journal of Kidney Diseases
2009
90
4
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Journal of Clinical Oncology
2013
67
5
Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients
Nephrology Dialysis Transplantation
2008
49
6
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
Journal of Clinical Oncology
2014
43
7
Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).
Journal of Clinical Oncology
2018
30
8
Evolving Statistical Methods to Facilitate Evaluation of the Causal Association Between Erythropoiesis-Stimulating Agent Dose and Mortality in Nonexperimental Research: Strengths and Limitations
American Journal of Kidney Diseases
2009
27
9
Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Journal of Clinical Oncology
2014
26
10
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Journal of Clinical Oncology
2013
21
11
Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).
Journal of Clinical Oncology
2018
20
site/software ©
exaly
; All materials licenced under
CC by-SA
.